Roivant Sciences Ltd.
41.81USD
+0.3300 (+0.80%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q1 FY27 | Q4 FY26* | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 3 | 2 | 2 | 2 | 8 | 9 | 4 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -366 | 415 | -339 | -306 | -285 | -285 | -274 | -342 |
| Net Income | -190 | 303 | -266 | -114 | -223 | -206 | 169 | -230 |
| EPS (Diluted) | $-0.26 | $0.34 | $-0.38 | $-0.17 | $-0.33 | $-0.29 | $0.23 | $-0.31 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)